Home / insider
Patel Sushil
Chief Executive Officer
Sushil Patel has served as a member of our Board and as our Chief Executive Officer since April 2024. Previously, Dr. Patel served as our Chief Strategy Officer from January 2023 to April 2024 and as our Chief Commercial Officer from May 2021 to January 2023. Prior to joining Replimune, Dr. Patel served as VP, Franchise Head for Lung, Skin, Tumor Agnostic, and Rare Cancers at Genentech, Inc. since April 2018, and previously held various positions of increasing responsibility at Genentech, Inc. since 2002, including global launch lead and lifecycle leader for Tecentriq in lung cancer. From 1999 to 2002, Dr. Patel served as Senior Consultant at Front Line Strategic Management Consulting. From 1996 to 1999,…
Biography from the company’s latest DEF 14A proxy statement
Revolution Medicines, Inc. 12 open-market prints by this insider, 4/10/2024 – 6/29/2026. Triangles mark only their Form 4 purchases and sales. Full RVMD chart
No daily prices for this ticker.
RVMD trades
| Date | Form 4 | Ticker | Side | Shares | Value | 90d | 180d |
|---|---|---|---|---|---|---|---|
| 6/29/2026 | Form 410b5-1 | Revolution Medicines, Inc · Biological Products, (No Diagnostic Substances)IndustryBiological Products, (No Diagnostic Substances) | SELL | 300 | $55.0K | −19.5%hist | +11.6%hist |
| 6/29/2026 | Form 410b5-1 | Revolution Medicines, Inc · Biological Products, (No Diagnostic Substances)IndustryBiological Products, (No Diagnostic Substances) | SELL | 900 | $166.1K | −19.5%hist | +11.6%hist |
| 6/29/2026 | Form 410b5-1 | Revolution Medicines, Inc · Biological Products, (No Diagnostic Substances)IndustryBiological Products, (No Diagnostic Substances) | SELL | 1,100 | $204.5K | −19.5%hist | +11.6%hist |
| 6/29/2026 | Form 410b5-1 | Revolution Medicines, Inc · Biological Products, (No Diagnostic Substances)IndustryBiological Products, (No Diagnostic Substances) | SELL | 858 | $160.4K | −19.5%hist | +11.6%hist |
| 6/29/2026 | Form 410b5-1 | Revolution Medicines, Inc · Biological Products, (No Diagnostic Substances)IndustryBiological Products, (No Diagnostic Substances) | SELL | 300 | $56.3K | −19.5%hist | +11.6%hist |
| 6/29/2026 | Form 410b5-1 | Revolution Medicines, Inc · Biological Products, (No Diagnostic Substances)IndustryBiological Products, (No Diagnostic Substances) | SELL | 100 | $18.9K | −19.5%hist | +11.6%hist |
| 6/29/2026 | Form 410b5-1 | Revolution Medicines, Inc · Biological Products, (No Diagnostic Substances)IndustryBiological Products, (No Diagnostic Substances) | SELL | 600 | $114.3K | −19.5%hist | +11.6%hist |
| 6/29/2026 | Form 410b5-1 | Revolution Medicines, Inc · Biological Products, (No Diagnostic Substances)IndustryBiological Products, (No Diagnostic Substances) | SELL | 541 | $103.8K | −19.5%hist | +11.6%hist |
| 6/29/2026 | Form 410b5-1 | Revolution Medicines, Inc · Biological Products, (No Diagnostic Substances)IndustryBiological Products, (No Diagnostic Substances) | SELL | 881 | $169.7K | −19.5%hist | +11.6%hist |
| 10/31/2024 | Form 410b5-1 | Revolution Medicines, Inc · Biological Products, (No Diagnostic Substances)IndustryBiological Products, (No Diagnostic Substances) | SELL | 5,000 | $270.7K | −19.5%hist | +11.6%hist |
| 7/9/2024 | Form 410b5-1 | Revolution Medicines, Inc · Biological Products, (No Diagnostic Substances)IndustryBiological Products, (No Diagnostic Substances) | SELL | 2,155 | $94.8K | −19.5%hist | +11.6%hist |
| 4/10/2024 | Form 410b5-1 | Revolution Medicines, Inc · Biological Products, (No Diagnostic Substances)IndustryBiological Products, (No Diagnostic Substances) | SELL | 2,155 | $79.7K | −19.5%hist | +11.6%hist |
Chart uses split-adjusted closes from the first print through the latest available bar. Returns use the last close on or before the trade date and the first close on or after 90 and 180 calendar days. Sales are signed so a declining price is a positive result for the seller. Not investment advice.